Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.

Clinical and experimental medicine - 1 Sept 2012

Rong Yefei, Qin Xia, Jin Dayong, Lou Wenhui, Wu Lili, Wang Dansong, Wu Wenchuan, Ni Xiaolin, Mao Zhengfa, Kuang Tiantao, Zang Ying Qin, Qin Xinyu

Abstract excerpt

The objectives of this study were to assess the toxicity and immunological response induced by the intra-dermal (i.d.) administration of MUC1-peptide-pulsed dendritic cells (DCs) in advanced pancreatic cancer patients. Patients with recurrent lesions or metastasis after surgery, and immunohistochemistry positive for MUC1 were treated in cohorts that received 3-6 × 10(6) DCs i.d. for three or four vaccines. Each...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunospot Assay

Share to Granzymes

Share to Immunity, Cellular

Share to Mucin-1

Share to Pilot Projects

Share to Vaccination

Source

Identifiers

PMID: 21932124
DOI: 10.1007/s10238-011-0159-0

Genes

MUC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.PMID 21932124Read ↗

Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.Semantic proximity Read ↗

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.Semantic proximity Read ↗

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.Semantic proximity Read ↗

A Double-blind Randomized Comparative Clinical Trial to Evaluate the Safety and Efficacy of Dendritic Cell Vaccine Loaded with WT1 Peptides (TLP0-001) in Combination with S-1 in Patients with Advanced Pancreatic Cancer Refractory to Standard ChemotherapySemantic proximity Read ↗

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?Semantic proximity Read ↗

Muc1 ImmunotherapySemantic proximity Read ↗

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trialSemantic proximity Read ↗

Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells.Semantic proximity Read ↗

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapySemantic proximity Read ↗

Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.Semantic proximity Read ↗

Dendritic cell therapy for skin cancer.Semantic proximity Read ↗

Phase I dendritic cell p53 peptide vaccine for head and neck cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.